The Trump administration recently released new details on its plan for drug pricing, which could potentially turn the healthcare industry on its head.
Hedgeye Health Policy analyst Emily Evans warns that any changes could potentially take years to implement, but some big pharma companies stand to win big under the Trump plan.
“It took us 50 years to get here. We’re not going to unwind this thing in a few weeks,” Evans explains in the clip above.
“You’re looking at a long trajectory of trying to take 20 to 30 billion dollars out of the system.”
Watch the clip above for more.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Editor’s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.